The estimated Net Worth of Neil Kumar is at least $200 Milhão dollars as of 16 August 2024. Neil Kumar owns over 55,537 units of BridgeBio Pharma Inc stock worth over $138,633,910 and over the last 6 years he sold BBIO stock worth over $35,393,755. In addition, he makes $26,334,100 as Chief Executive Officer e Director at BridgeBio Pharma Inc.
Neil has made over 40 trades of the BridgeBio Pharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 55,537 units of BBIO stock worth $1,554,481 on 16 August 2024.
The largest trade he's ever made was buying 1,103,848 units of BridgeBio Pharma Inc stock on 24 May 2019 worth over $28,622,779. On average, Neil trades about 120,689 units every 49 days since 2018. As of 16 August 2024 he still owns at least 4,952,980 units of BridgeBio Pharma Inc stock.
You can see the complete history of Neil Kumar stock trades at the bottom of the page.
Dr. Neil Kumar Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Kumar has also served as the Chief Executive Officer of our subsidiary, Eidos Therapeutics (Nasdaq: EIDX), a clinical stage biopharmaceutical company, and a member of Eidos Therapeutics’ board of directors since March 2016. Prior to that, he served as the interim vice president of business development at MyoKardia, Inc. (Nasdaq: MYOK), a clinical stage biopharmaceutical company, from 2012 to 2014. Prior to that, Dr. Kumar served as a principal at Third Rock Ventures, a venture capital firm, from 2011 to 2014. Before joining Third Rock Ventures, he served as an associate principal at McKinsey & Company, a worldwide management consulting firm, from 2007 to 2011. He received his B.S. and M.S. degrees in chemical engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology. Dr. Kumar’s qualifications to serve on our Board of Directors include his role as our principal executive officer and his extensive experience as an executive officer of biotechnology companies.
As the Chief Executive Officer e Director of BridgeBio Pharma Inc, the total compensation of Neil Kumar at BridgeBio Pharma Inc is $26,334,100. There are no executives at BridgeBio Pharma Inc getting paid more.
Neil Kumar is 41, he's been the Chief Executive Officer e Director of BridgeBio Pharma Inc since 2015. There are 16 older and 6 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
Neil's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo, eGenetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include: